Beijing Sanbo Brain Hospital
25
10
12
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
4.0%
1 terminated/withdrawn out of 25 trials
90.0%
+3.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (25)
The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With Fibromyalgia
Role: collaborator
Observational Study on Dynamic Changes of Blood Pressure During Post-epileptic Seizure Stage (OCBPS)
Role: collaborator
Intraoperative Diaphragmatic Neuromodulation
Role: lead
Subthalamic Nucleus Electrical Stimulation for Drug-resistant Focal Motor Epilepsy
Role: collaborator
Electroencephalogram Predicts Post-operative Delirium
Role: lead
M-I/E for Preventing VAP in Post-neurosurgical Patients
Role: lead
Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery
Role: collaborator
The Effectiveness and Safety of Resective Epilepsy Surgery for TRE
Role: collaborator
Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas
Role: lead
Retrospective Study of Germ Cell Tumors of the Central Nervous System
Role: lead
Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)
Role: lead
Modified CV Regimen in Optic Pathway Glioma
Role: lead
Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children
Role: lead
Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults
Role: lead
Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Role: lead
Post-neurosurgical Respiratory Muscle Dysfunction
Role: lead
Mechanical Ventilation on Hippocampus
Role: lead
A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse
Role: lead
Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas
Role: lead
Glioblastoma Response Prediction to Apatinib
Role: lead